Moderna, Inc. (MRNA) Stock Price & Analysis
Moderna, Inc. (MRNA) fell 5.17% to USD 54.07 as of July 25, 2026 at 01:12 UTC, according to Nexqual real-time market data.
MRNA last closed at USD 57.02; the session ranged USD 53.85–57.46 on volume of 4,321,319 shares. Market capitalization is $21.45B, with a 52-week range of USD 22.28–85.6 (NMS). Source: Nexqual, July 25, 2026 at 01:12 UTC.
Key Statistics (as of July 25, 2026 at 01:12 UTC)
| Price | USD 54.07 |
|---|---|
| Change | ▼ 5.17% (down) |
| Previous Close | USD 57.02 |
| Open | USD 57.26 |
| Day Range | USD 53.85 – 57.46 |
| 52-Week Range | USD 22.28 – 85.6 |
| Volume | 4,321,319 shares |
| Market Cap | $21.45B |
| Exchange | NMS |
Technical Analysis (MRNA)
Nexqual's technical model rates MRNA "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:12 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.05 (neutral) |
| vs SMA50 | Below (USD 57.7) |
| MACD | -0.77 (negative) |
Analyst Ratings (MRNA)
Wall Street analysts rate MRNA "Hold" based on 19 analysts, with a mean price target of USD 49.37 (range USD 25–79), per Nexqual as of July 25, 2026 at 01:12 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 19 |
| Mean Target | USD 49.37 |
| High Target | USD 79 |
| Low Target | USD 25 |
| Buy / Hold / Sell | 4 / 16 / 3 |
Earnings (MRNA)
| Next Earnings Date | 2026-07-31 |
|---|---|
| EPS Estimate | USD -2 |
| Revenue Estimate | $103.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -3.4 vs est -3.88 ▲ beat |
| 2025-12-31 | USD -2.11 vs est -2.6 ▲ beat |
| 2025-09-30 | USD -0.51 vs est -2.18 ▲ beat |
| 2025-06-30 | USD -2.13 vs est -2.97 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financials & Fundamentals (MRNA)
| Total Revenue | $2.22B |
|---|---|
| Revenue Growth (YoY) | +260.20% |
| Gross Margin | -69.89% |
| Operating Margin | -131.10% |
| Profit Margin | -143.55% |
| ROE | -36.56% |
| Debt / Equity | 17.52 |
| Current Ratio | 2.41 |
| Total Cash | $5.21B |
| Total Debt | $1.30B |
| Free Cash Flow | $-20.00M |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Financial Health Score (MRNA)
Nexqual rates Moderna, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 01:12 UTC.
| Growth | Critical — Revenue -40% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $5.21B cash vs $1.30B debt, net cash position |
| Cash Flow | Weak — FCF negative: -$20M, burning cash |
| Efficiency | Critical — ROE -37%, ROA -13.1% |
Ownership (MRNA)
| Insider Ownership | +7.31% |
|---|---|
| Institutional Ownership | +78.84% |
| Shares Outstanding | 396.79M |
| Float | 370.06M |
| Short % of Float | +16.40% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
Leadership (MRNA)
Moderna, Inc. is led by Stéphane Bancel (age 52), CEO & Director, per Nexqual as of July 25, 2026 at 01:12 UTC.
| CEO & Director | Stéphane Bancel (age 52) |
|---|---|
| President | Stephen Hoge (age 49) |
| Chief Financial Officer | James M. Mock (age 48) |
| Senior Vice President of Commercial Vaccines | Patrick Norman Bergstedt (age 63) |
Major Backers & Investors (MRNA)
Notable institutional backers of Moderna, Inc. include FMR, LLC, Baillie Gifford, Capital Group, according to Nexqual as of July 25, 2026 at 01:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 11.51% |
| Baillie Gifford | 5.04% |
| Capital Group | 4.71% |
| GROWTH FUND OF AMERICA | 3.15% |
| Fidelity | 2.68% |
| Two Sigma Investments, LP | 2.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 19.67% |
| BlackRock | 8.62% |
| State Street | 3.75% |
| Geode Capital | 2.38% |
Source: Nexqual, July 25, 2026 at 01:12 UTC.
From Moderna, Inc.'s Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Any mRNA and LNP components that do not escape the endosome are typically delivered to lysosomes where they are degraded by the natural process of cellular digestion. 9 Table of Contents Examples of tools we developed by using our platform include proprietary LNP formulations that address the steps of mRNA delivery, including cell uptake, endosomal escape, and subsequent lipid metabolism, and for avoidance of counterproductive interactions with the immune system.
- We pursue updated vaccine compositions based on guidance from the FDA, and other regulatory bodies including European Medicines Agency (EMA) and the World Health Organization (WHO), with the goal of broadening vaccine-induced immunity and providing protection against circulating SARS-CoV-2 variants.
- We have developed an RSV vaccine (mRNA-1345 or mRESVIA) for adults. mRESVIA encodes an engineered form of the RSV F protein stabilized in the prefusion conformation and is formulated in our proprietary LNP.
- We filed for FDA approval for mRNA-1083 in November 2024 and also submitted regulatory applications in other geographies, including the EU, Canada, Australia and the UK.
Partnerships
- In September 2022, Merck exercised its option for personalized cancer vaccines (PCVs), including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement, also referred to as the INT Agreement).
- In January 2026, we entered into a strategic collaboration with Recordati, an international pharmaceutical group, to advance mRNA-3927 through the final stages of clinical development and, if approved, global commercialization.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVAX | Novavax, Inc. | USD 7.46 | ▼ 5.69% |
| BNTX | BioNTech SE | USD 89.33 | ▼ 2.72% |
| ZM | Zoom Communications, Inc. | USD 87.99 | ▲ 2.54% |
| AZN | AstraZeneca PLC | USD 169.26 | ▼ 0.28% |
| NIO | NIO Inc. | USD 4.49 | ▼ 3.85% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:12 UTC. This page is informational and not investment advice.